Agenus | AGEN - Operating Expenses


Agenus reported $-274.14M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Agenus USD -274.14M 80.46M Sep/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Celldex Therapeutics USD 598.36M 533.78M Sep/2025
CSL USD 2.87B 2.85B Jun/2025
Dynavax Technologies USD 73.6M 7.41M Sep/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Incyte USD 1.12B 3.53B Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
J&J USD 18.97B 2.38B Dec/2025
Jiangsu Hengrui CNY 5.94B 254.97M Sep/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
MacroGenics USD 67M 8M Sep/2025
Merck EUR 4.11B 117M Sep/2025
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Novavax USD 218.53M 34.86M Sep/2024
Pfizer USD 12.91B 79.89B Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Veracyte USD 108.76M 7.09M Sep/2025